EXEL (EXELISIS INC) P/E: 800 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.31 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.24 DIVIDEND: none Exilixis is a pharmaceutical company specializing in cancer drugs. The company is up already over 60% YTD. It is heavily owned by the major institutions. In each of the last 4 quarters, EXEL has beat Wall Street expectations, according to Estimize. The last two quarters have been profitable, and the company has set its expectations for profitable quarters in the future. Previously, the company posted consistent losses. Revenue increased approximately 550% on a year-over-year basis, while collaborative revenue doubled. EXEL has partnerships with Roche and GlaxoSmithKline. Cabometyx, a rectal cancer drug, is its largest revenue source in the latest quarter and most recent drug launch for the company. Exelixis announced that their R&D budget decreased due to decreased costs in one of their drug s...
Unbiased stock market analysis utilizing knowledge obtained from Mad Money, several books on the stock market, and market experience. No description on my site constitutes stock market advice, nor do I make any promise of profit here. However, I really hope this information does help you to earn some of that sweet dosh for yourself!